Italian regulators and industry pledge to get act together for biotech clinical trials
This article was originally published in SRA
Italian biotechnology association Assobiotec has signed a deal with the national drug regulator AIFA and the national health institute (ISS) aimed at providing a more favourable environment for early clinical trials to be conducted in Italy1. At base, the deal has extracted public promises from the authorities to execute their parts in the drug development process in a timely and effective manner in exchange for a commitment from the industry association to encourage its members to conduct early clinical work in Italy.
You may also be interested in...
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.